Malarone (Proguanil Hydrochloride, Atovaquone)

Atovaquone blocks the parasite’s mitochondrial electron transport chain, halting energy production, while proguanil is converted to cycloguanil, which inhibits dihydrofolate reductase, disrupting DNA synthesis. The combined effect provides a potent, synergistic antimalarial action.

The specific dosage and treatment schedule for Malarone are determined by a qualified prescriber based on the indication, patient weight, age, and local resistance patterns. Patients should follow the exact instructions provided by their healthcare professional.

Safety data for Malarone in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing women.

To request Malarone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malarone offers a convenient once‑daily oral regimen and combines two mechanisms of action, which can reduce the risk of resistance compared with single‑agent therapies such as chloroquine or mefloquine. It is generally well‑tolerated but may be less suitable in areas with documented atovaquone‑proguanil resistance.

Malarone tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect them from moisture and light. Do not store in extreme heat or humidity to maintain product stability.

Malarone is taken orally with food or a milky drink to enhance absorption. For prophylaxis, it is usually started 1–2 days before travel, taken daily throughout exposure, and continued for 7 days after leaving the endemic area. For treatment, the full prescribed course should be completed.

Serious adverse events, though rare, include severe skin reactions such as Stevens‑Johnson syndrome, liver injury, hemolysis in patients with G6PD deficiency, and severe allergic reactions. Patients should seek immediate medical attention if they develop rash, jaundice, dark urine, or signs of anaphylaxis.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. It should also be avoided in patients with severe renal impairment unless dose‑adjusted by a physician, and in those with documented resistance to the drug combination.